Octreotide as an agent for the relief of malignant ascites in palliative care patients

Palliative Medicine

Volumn 13, Issue 5, 1999, Pages 429-430

  Cairns, Will ^a   Malone, Richard ^b  

^a TOWNSVILLE HOSPITAL   (Australia)

^b MACKAY BASE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOTHALAMUS RELEASE INHIBITING FACTOR; OCTREOTIDE;

ADULT; ARTICLE; ASCITES; BRAIN METASTASIS; BREAST CANCER; CASE REPORT; COLON CARCINOMA; DIARRHEA; DRUG EFFICACY; FEMALE; FISTULA; HUMAN; INTESTINE OBSTRUCTION; LIVER METASTASIS; MALE; PALLIATIVE THERAPY; PARACENTESIS; SUBCUTANEOUS DRUG ADMINISTRATION;

ADENOCARCINOMA; AGED; ASCITES; COLONIC NEOPLASMS; GASTROINTESTINAL AGENTS; HUMANS; MALE; MIDDLE AGED; OCTREOTIDE; PALLIATIVE CARE;

EID: 0032830056     PISSN: 02692163     EISSN: None     Source Type: Journal    
DOI: 10.1191/026921699677473561     Document Type: Article

References (6)

1. Riley J, Fallon MT. Octreotide in terminal malignant obstruction of the gastrointestinal tract. Eur J Palliat Care 1994; 1: 23-25.
2. Mercadante S. The role of octreotide in palliative care. J Pain Symp Manage 1994; 6: 406-11.
3. Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ. Octreotide. N Engl J Med 1996; 334: 246-54.
4. Penn RD, Paice JA, Kroin JS. Octreotide: a potent new nonopiate analgesic for intrathecal infusion. Pain 1992; 49: 13-19.
5. Harvey MK, Dunlop RJ. Octreotide and the secretory effects of advanced cancer. Palliat Med 1996: 10: 346-47.
6. Peckham MJ, Pinedo H, Veronesi U eds. Oxford textbook of oncology. Oxford: Oxford University Press, 1995: 2271-74.